XML 45 R19.htm IDEA: XBRL DOCUMENT
v3.19.3

Reportable Segment Information | 12 Months Ended
--- | ---
Sep. 30, 2019
Segment Reporting [Abstract] |
Reportable Segment Information | 11. Reportable Segment Information The accounting standards for reporting information about operating segments define operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. For financial accounting and reporting purposes, the Company reports its results for the two reportable segments as follows: (1) the Medical Device unit, which designs, develops and manufactures interventional medical devices, primarily for the peripheral vascular market; surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings. The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):
|  | 2019 |  |  | 2018 |  |  | 2017 |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Medical Device |  | $ | 78,353 |  |  | $ | 60,513 |  |  | $ | 53,983 |
In Vitro Diagnostics |  |  | 21,724 |  |  |  | 20,823 |  |  |  | 19,129 |
Total revenue |  | $ | 100,077 |  |  | $ | 81,336 |  |  | $ | 73,112 |
Operating income (loss): |  |  |  |  |  |  |  |  |  |  |  |
Medical Device |  | $ | 4,794 |  |  | $ | (8,478 | ) |  | $ | 6,902 |
In Vitro Diagnostics |  |  | 10,620 |  |  |  | 8,619 |  |  |  | 8,293 |
Total segment operating income |  |  | 15,414 |  |  |  | 141 |  |  |  | 15,195 |
Corporate |  |  | (8,945 | ) |  |  | (8,940 | ) |  |  | (8,092 | )
Total operating income (loss) |  | $ | 6,469 |  |  | $ | (8,799 | ) |  | $ | 7,103 |
Depreciation and amortization: |  |  |  |  |  |  |  |  |  |  |  |
Medical Device |  | $ | 5,811 |  |  | $ | 5,376 |  |  | $ | 4,453 |
In Vitro Diagnostics |  |  | 464 |  |  |  | 394 |  |  |  | 412 |
Corporate |  |  | 1,037 |  |  |  | 661 |  |  |  | 690 |
Total depreciation and amortization |  | $ | 7,312 |  |  | $ | 6,431 |  |  | $ | 5,555 |
The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments. Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available. Major Customers Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:
|  | 2019 |  |  | 2018 |  |  | 2017 |
Abbott |  |  | 19 | % |  |  | 11 | % |  | N/A |
Medtronic |  |  | 14 | % |  |  | 16 | % |  |  | 18 | %
The revenue from the customers listed is derived from two primary sources: licensing and product sales (primarily in the Medical Device segment). Geographic Revenue and Long-lived Assets Geographic revenue was as follows for the years ended September 30:
|  | 2019 |  |  | 2018 |  |  | 2017 |
Domestic |  |  | 81 | % |  |  | 79 | % |  |  | 77 | %
Foreign |  |  | 19 | % |  |  | 21 | % |  |  | 23 | %
Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30:
|  | 2019 |  |  | 2018 |
U.S. |  | $ | 24,450 |  |  | $ | 26,652 |
Ireland |  |  | 19,524 |  |  |  | 21,174 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration